BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9134274)

  • 21. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension.
    Erdem Y; Usalan C; Haznedaroğlu IC; Altun B; Arici M; Yasavul U; Turgan C; Cağlar S
    Am J Hypertens; 1999 Nov; 12(11 Pt 1):1071-6. PubMed ID: 10604482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term effects of angiotensin receptor blockers on blood pressure control, and plasma inflammatory and fibrinolytic parameters in patients taking angiotensin-converting enzyme inhibitors.
    Agirbasli M; Cincin A; Baykan OA
    J Renin Angiotensin Aldosterone Syst; 2008 Mar; 9(1):22-6. PubMed ID: 18404606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction.
    Jansson JH; Boman K; Nilsson TK
    Eur J Clin Pharmacol; 1993; 44(5):485-8. PubMed ID: 8359188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
    Wiman B; Andersson T; Hallqvist J; Reuterwall C; Ahlbom A; deFaire U
    Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):2019-23. PubMed ID: 10938026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of tissue-type plasminogen activator-mediated fibrinolysis by plasminogen activator inhibitor type-1 in patients with ischaemic heart disease: possible unfavourable effect of diuretics.
    Pedersen OD; Gram J; Bagger H; Keller N; Jespersen J
    Coron Artery Dis; 1994 Jul; 5(7):617-23. PubMed ID: 7952424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Steady-state pharmacokinetics and pharmacodynamics of imidaprilat, an active metabolite of imidapril, a new angiotensin-converting enzyme inhibitor in spontaneously hypertensive rats.
    Yamanaka K; Takehara N; Murata K; Banno K; Sato T
    J Pharm Sci; 1996 Nov; 85(11):1234-7. PubMed ID: 8923331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time.
    Brown NJ; Kumar S; Painter CA; Vaughan DE
    Hypertension; 2002 Dec; 40(6):859-65. PubMed ID: 12468570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-finding study of imidapril, a novel angiotensin converting enzyme inhibitor, in patients with stable chronic heart failure.
    Pinto YM; van Veldhuisen DJ; Tjon-Ka-Jie RT; Rooks G; Netzer T; Lie KI
    Eur J Clin Pharmacol; 1996; 50(4):265-8. PubMed ID: 8803516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Plasminogen activator inhibitor-1 (PAI-1) 4G/5G and angiotensin converting enzyme (ACE) I/D gene polymorphisms and fibrinolytic activity in patients with essential hypertension and dyslipidemia].
    Jastrzebska M; Widecka K; Ciechanowicz A; Goracy I; Wesołowska T; Torbus-Lisiecka B; Foltyńska-Nowakowska A; Naruszewicz M
    Pol Arch Med Wewn; 2005 Jan; 113(1):7-20. PubMed ID: 16130596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype.
    Ohmichi N; Iwai N; Uchida Y; Shichiri G; Nakamura Y; Kinoshita M
    Am J Hypertens; 1997 Aug; 10(8):951-5. PubMed ID: 9270093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.
    Brown NJ; Agirbasli M; Vaughan DE
    Hypertension; 1999 Aug; 34(2):285-90. PubMed ID: 10454455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose finding studies with imidapril--a new ACE inhibitor.
    Vandenburg MJ; Mackay EM; Dews I; Pullan T; Brugier S
    Br J Clin Pharmacol; 1994 Mar; 37(3):265-72. PubMed ID: 8198936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
    Tiryaki O; Usalan C; Buyukhatipoglu H
    Nephrology (Carlton); 2010 Mar; 15(2):211-5. PubMed ID: 20470281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
    Lindgren A; Lindoff C; Norrving B; Astedt B; Johansson BB
    Stroke; 1996 Jun; 27(6):1066-71. PubMed ID: 8650716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Studies on angiotensin I converting enzyme (ACE): inhibitory effect of imidapril, a novel ACE inhibitor (II). Inhibition of various tissue ACEs ex vivo].
    Hashimoto Y; Kubo M; Sugaya T; Minobe S; Watanabe T; Yamamura M; Matsuoka Y
    Nihon Yakurigaku Zasshi; 1994 Jul; 104(1):51-61. PubMed ID: 8076891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin-converting enzyme inhibition alters the fibrinolytic response to cardiopulmonary bypass.
    Pretorius M; Murphey LJ; McFarlane JA; Vaughan DE; Brown NJ
    Circulation; 2003 Dec; 108(25):3079-83. PubMed ID: 14656921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin-converting enzyme inhibition augments coronary release of tissue plasminogen activator in women but not in men.
    Matsumoto T; Takashima H; Nakae I; Yamane T; Hayashi H; Horie M;
    Hypertension; 2010 Sep; 56(3):364-8. PubMed ID: 20606106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of high plasma levels of angiotensin-converting enzyme (ACE) and plasminogen activator inhibitor (PAI-1) on the reperfusion after thrombolytic therapy in patients presented with acute myocardial infarction.
    El Menyar AA; Altamimi OM; Gomaa MM; Fawzy Z; Rahman MO; Bener A
    J Thromb Thrombolysis; 2006 Jun; 21(3):235-40. PubMed ID: 16683215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1.
    Brown NJ; Agirbasli MA; Williams GH; Litchfield WR; Vaughan DE
    Hypertension; 1998 Dec; 32(6):965-71. PubMed ID: 9856958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasminogen activator inhibitor-1 and angiotensin I converting enzyme gene polymorphism in patients with hypertension.
    Jeng JR; Harn HJ; Yueh KC; Jeng CY; Shieh SM
    Am J Hypertens; 1998 Feb; 11(2):235-9. PubMed ID: 9524054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.